Products for Research Use Only

Regorafenib (mesylate)

CAT: 0804-HY-10331BSize: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10331BSize:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Regorafenib (BAY 73-4506) mesylate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib mesylate shows very robust antitumor and antiangiogenic activity[1].
CAS Number
835621-08-4
Product Name Alternative
BAY 73-4506 (mesylate)
UNSPSC
12352005
Target
Autophagy; c-Kit; FGFR; PDGFR; Raf; RET; Tie; VEGFR
Type
Reference compound
Related Pathways
Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/regorafenib-mesylate.html
Solubility
10 mM in DMSO
Smiles
O=C(NC1=CC=C(C(C(F)(F)F)=C1)Cl)NC2=CC=C(OC3=CC(C(NC)=O)=NC=C3)C=C2F.CS(O)(=O)=O
Molecular Formula
C22H19ClF4N4O6S
Molecular Weight
578.92
References & Citations
[1]Wilhelm SM, et al. Regorafenib (BAY 73-4506) : a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer, 2011, 129 (1), 245-255.|[2]Carr BI, et al. Fluoro-Bay 43-9006 (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol, 2013, 228 (2), 292-297.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
B-Raf; C-Raf; PDGFRβ; Tie2; VEGFR1/Flt-1; VEGFR2/KDR/Flk-1; VEGFR3/Flt-4